Immortal time bias in observational analyses of linezolid interruption and rechallenge

The Lancet Global Health · Published 2026-06-03 · DOI 10.1016/j.langlo.2026.103978

Free full text

Authors (2)

Matthew Romo, Molly F Franke

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Romo, M., Franke, M. (2026). Immortal time bias in observational analyses of linezolid interruption and rechallenge. The Lancet Global Health. https://doi.org/10.1016/j.langlo.2026.103978

Related articles

• WHO foodborne disease estimates 2000–21: bridging the burdens of infectious and non-communicable diseases · The Lancet Global Health · 2026 · Same journal
• PABS and the dangerous temptation of more time · The Lancet Global Health · 2026 · Same journal
• Prevalence of vision and hearing impairment in Australia: a nationally representative survey of Indigenous and non-Indigenous Australians aged 50 years and older · The Lancet Global Health · 2026 · Same journal
• Incidence of symptomatic Lassa virus infection in West African countries (Enable 1.0 Lassa Research Study): a prospective, multisite, cohort study · The Lancet Global Health · 2026 · Same journal
• The overlooked role of local frontline health workers in the Bundibugyo Ebola response · The Lancet Global Health · 2026 · Same journal
• Mexico’s Servicio Universal de Salud: a pathway to integration and universal health coverage? · The Lancet Global Health · 2026 · Same journal
• Strengthening infection prevention in long-term care facilities in low-income and middle-income countries · The Lancet Global Health · 2026 · Same journal
• WHO estimates of the global, regional, and national burden of 14 foodborne diarrhoeal enteric hazards, 2000–21: an updated data synthesis · The Lancet Global Health · 2026 · Same journal
• Decolonising implementation science: Southeast Asian perspectives · The Lancet Global Health · 2026 · Same journal
• Phone-based screening versus home-based screening after tuberculosis in India (TB Aftermath): a multicentre, open-label, randomised, controlled, non-inferiority trial · The Lancet Global Health · 2026 · Same journal